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BACKGROUND: Myocardial infarction (MI) as a term for a 
heart attack happens due to reduced blood flow to heart 
myocardium and lack of oxygen supply caused by plaques in 
the interior walls of coronary arteries. With respect to the 
importance of MI etiology, we aimed to study the relationship 
of MI and blood examination variables. 
METHODS: This study was conducted in Mazandaran Heart 
Center as a hospital-based case-control Comprising 894 
participants including 465 cases and 429 controls, 
individually matched by sex and age. Considered blood 
markers were analyzed using routine laboratory methods and 
equipment. 
RESULTS: Of all participants, 64.3% of the cases and 51.0% 
of the controls were males with a mean age of 61.2 (±13.8) in 
cases and 62.4 (±14.) in controls. We could not find any 
differences between cases and controls for total cholesterol 
(TC), low-density lipoprotein (LDL), high-density lipoprotein 
(HDL), and alkaline-phosphatase (ALP) (P>0.05). However, 
levels of creatine-kinase-muscle/brain (CK-MB) (P<0.0001), 
fasting-blood-sugar (FBS) (P<0.0001), aspartate-
aminotransferase (AST) (P<0.0001), alanine-transferase 
(ALT) (P<0.0001) and erythrocyte sedimentation rate (ESR) 
(P=0.001) were significantly higher in cases compared to the 
controls (P<0.05). Multivariable analyses revealed that the 
risk of MI was associated with high levels of AST (adjusted 
OR=24.3, 95%CI=3.5±165.6, P=0.001) and LDL (adjusted 
OR=7.4, 95%CI=1.0±51.8, P=0.001). 
CONCLUSION: Our investigation indicated that the levels of 
CK-MB, FBS, AST, ALT and ESR were significantly higher 
in patients with MI. Besides, our findings showed that the 
risk of MI in cases with high levels of AST and LDL was 
about 24 and 7 times more than the control group 
respectively. 
KEYWORDS: Cardiovascular Stroke, Heart Attack, 
Biochemical Markers, Serum Marker, Laboratory Markers  
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Myocardial infarction (MI) is defined as the 
presence of acute myocardial injury detected by 
abnormal cardiac biomarkers in the setting of 
evidence of acute myocardial ischemia (1). MI 
happens due to reduced blood flow to heart 
myocardium and lack of oxygen supply caused by 
plaques in the interior walls of coronary arteries (2). 
It is a major cause of death and disability worldwide 
(3). Over 15% of mortalities worldwide happens due 
to MI each year (4). According to the global burden 
of disease report 2017, cardiovascular diseases are 
the leading cause of death in Iran with 196.32 in 
100/000 people (5). There are approximately 3.6 
million patients with cardiovascular disease in Iran, 
and MI is responsible for 46% deaths due to 
cardiovascular diseases (6). 
In the clinical aspect, there is quite a number of 
enzymes, hormones, biological substances and other 
biomarkers derived from blood or urine that can be 
used in diagnosis (7). Since only myocardium 
contains a considerable amount of creatine kinase-
muscle/brain (CK-MB), measuring CK-MB 
isoenzyme is a good indicator of MI (8). CK-MB 
appears 4 to 6 hours after the onset of chest pain, and 
it consists nearly 30% of CK in the myocardium (9). 
Plasma lipoproteins are risk factors for 
cardiovascular (CV) events after MI. High levels of 
low-density lipoprotein (LDL) is associated with 
increased risk of CV and high levels of high-density 
lipoprotein (HDL) associated with decreased risk of 
CV. Decreased LDL and variable HDL levels have 
been reported after MI and increased risk of in-
hospital mortality was associated with lower LDL 
levels (10). 
Nonspecific tests which indicate inflammation 
can be used to diagnose various diseases. The 
inflammatory response following MI causes an 
increased erythrocyte sedimentation rate (ESR) 
(11). ESR is also a significant predictor of heart 
failure and might be useful for the diagnostic 
criterion for coronary heart disease (12). High levels 
of blood sugar can increase the risk of death and 
poor outcome in patients with MI, and it is 
associated with increased risk of in-hospital 
mortality in these patients (13). Fasting 
hyperglycemia in early MI could be a marker for 
high-risk individuals (14). Liver markers can also 
predict the outcome of patients after acute 
myocardial infarction. Increased serum level of 
alanine transferase (ALT) and aspartate 
aminotransferase (AST) are associated with a higher 
risk of CV events. ALT and AST can be elevated 
due to cardiac failure, and AST can be significantly 
correlated with death (15). Serum alkaline 
phosphatase (ALP) is also a good prognostic factor 
in MI patients (16). 
Since clinical symptoms are not reliable 
enough in the diagnosis of MI and 
electrocardiography (ECG) can show uncertain 
patterns, serum biochemical markers can be helpful 
in confirming and diagnosis of MI (17). With 
respect to the importance of MI etiology using blood 
biomarkers, we aimed to investigate the relationship 
between MI and blood biomarkers in Mazandaran 
Heart Center. 
 
MATERIALS AND METHODS 
 
Study design: In this hospital-based case-control 
study, data were obtained from all patients admitted 
to the Mazandaran Heart Center in Sari city for the 
period of three months during students’ internship in 
this center. This tertiary center is the largest heart 
center in the north of Iran, and most of the patients 
referred to this center are Mazandaranis. The study 
was conducted from September 2018 to December 
2018 (according to the Persian solar calendar). 
 
Study population: Hospitalized patients diagnosed 
with MI based on diagnostic criteria of the European 
Society of Cardiology (ESC) and the American 
College of Cardiology (ACC) guidelines (18) 
entered into our study as cases. Sex- and age-
matched (± 1 years) seemingly healthy people, 
without a history of MI and negative troponin test 
participated in our study as controls. All of the 
participants were from the same geographic 
background (Mazandaranis). A consent letter was 
obtained from all participants, and no one refused to 
participate in the study. Exclusion criteria were as 
follows: 1) age under 18 years, 2) history of 
malignancy, 3) pregnant women, 4) insufficient 
medical record, and 5) participation refusal. 
 
Laboratory measurements: After at least eight 
hours overnight fasting, blood samples were drawn 
from all participants. Serum levels of CK-MB, 
fasting blood sugar (FBS), total cholesterol (TC), 
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LDL, HDL, AST, ALT, and ALP were determined 
using the automatic biochemistry analyzer (Hitachi 
912, Fameco, Japan). Troponin levels were analyzed 
using MINI VIDAS® immunoanalyzer (bioMérieux, 
France). According to Westergren method, whole 
blood of the patients was mixed with sodium citrate 
in a standardized calibrated tube, which are allowed 
to sit for 60 minutes in the LENA ESR analyzer to 
measure the sedimentation level. 
 
Statistical analysis: The Statistical Package for the 
Social Sciences 16.0 (SPSS Inc., Chicago, Illinois, 
USA) was used for data analysis. A descriptive 
analysis of categorical variables was performed 
using frequencies and percentages. Variables 
comparisons were calculated using chi-square or 
Fisher exact tests, as appropriate. CK-MB>190, 
FBS>115, TC>200, LDL>160, HDL<40, AST>35, 
ALT>40, ALP>306 and ESR>20 were considered 
as abnormal levels. Comparisons of cases and 
controls regarding study variables were performed 
using the unpaired t-test or ANOVA for normally 
distributed parameters. In order to evaluate the 
interactive effects of study variables on MI 
occurrence, we used logistic regression model to 
calculate the odds ratio (OR) with 95% confidence 
interval (95% CI). A P-value less than 0.05 was 
considered statistically significant. 
This study was approved in the Ethical Review 
Committee of the Mazandaran University of 
Medical Science (MAZUMS) with ethical code 
IR.MAZUMS.REC.1398.469. The Student 
Research Committee of the MAZUMS sent a 
request to the Mazandaran Heart Center for 
collaboration. To comply with ethical standards, the 
consent form was filled out with all participants and 
their medical records were used confidentiality, 




In total, 894 subjects: 465 cases including 299 
(64.3%) males and 166(35.7%) females and 429 
controls including 219(51.0%) males and 210 
(49.0%) females, which matched by sex and age 
participated in the investigation. The characteristics 
of the cases and controls are presented in Table 1. 
 
Table 1: Demographical and laboratory characteristics of the cases and controls 
 
Variable Case (n=465) Control (n=429) P-value 
Sex, male n (%) 299 (64.3) 219 (51.0) matched 
Age, years* 61.2 ±13.8 62.4 ±14.1 matched 
CK-MB, IU/L* 108.3 ± 155.6 42.0 ± 88.9 <0.0001 
FBS, mg/dL* 131.4 ± 78.4 101.5 ± 44.2 <0.0001 
TC, mg/dL* 174.5 ± 49.7 178.8 ± 101.6 0.340 
LDL, mg/dL* 150.6 ± 768.8 99.2 ± 42.7 0.103 
HDL, mg/dL* 36.6 ± 12.1 36.6 ± 13.0 0.754 
ESR, mm/h* 47.0 ± 48.7 28.5 ± 27.3 0.001 
 
CK-MB: creatine kinase-muscle/brain; FBS: Fasting Blood Sugar; TC: Total Cholesterol; LDL: Low-Density 
Lipoprotein; HDL: High-Density Lipoprotein; AST: Aspartate Aminotransferase; ALT: Alanine transaminase; ALP: 
Alkaline phosphatase; ESR: Erythrocyte Sedimentation Rate. ∗mean ± SD 
The mean age of cases was 61.2 years (±13.8) while 
the mean age of controls was 62.4 years (±14.1). 
There were no differences between cases and 
controls regarding TC, LDL, HDL, and ALP. 
As a cardiac marker, CK-MB levels were higher in 
MI patients in comparison to the control group 
(P<0.0001). The mean amount of FBS was 
significantly higher in cases than in controls 
(P<0.0001). Regarding liver enzymes, although 
levels of ALP was not different between the two 
groups, levels of both AST (P<0.0001) and ALT 
(P<0.0001) were significantly higher in cases than 
controls. Moreover, level of ESR was meaningfully 
higher in cases (P=0.001). 
Multivariable analyses revealed that the 
increase in risk for MI was associated with high 
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levels of AST (adjusted OR=24.3, 
95%CI=3.5±165.6, P=0.001) and LDL (adjusted 
OR=7.4, 95%CI=1.0±51.8, P=0.001). However, no 
significant relationships were observed for other 
parameters. Risk estimates were present in Table 2. 
 
Table 2: Associations between considered variables and risk of Myocardial infarction 
 
Variable OR* (95%CI) P-value 
Sex 0.050 (0.008-0.308) 0.001 
Age 0.980 (0.934-1.028) 0.415 
CK-MB 0.209 (0.003-15.391) 0.475 
FBS 2.365 (0.511-10.948) 0.271 
TC 0.566 (0.107-2.990) 0.503 
LDL 7.481 (1.080-51.806) 0. 042 
HDL 3.629 (0. 757-17.396) 0.107 
AST 24.366 (3.583-165.697) 0.001 
ALT 0.791 (0.063-9.879) 0.856 
ALP 1.857 (0.376-9.166) 0.447 
ESR 0.263 (0.043-1.616) 0.149 
 
CK-MB: creatine kinase-muscle/brain; FBS: Fasting Blood Sugar; TC: Total Cholesterol; LDL: Low-Density Lipoprotein; 
HDL: High-Density Lipoprotein; AST: Aspartate Aminotransferase; ALT: Alanine transaminase; ALP: Alkaline 
phosphatase; ESR: Erythrocyte Sedimentation Rate.  
*Adjusted by age and sex 
 




Our investigation indicated that levels of CK-MB, 
FBS, AST, ALT, and ESR were significantly higher 
in patients with MI. Besides, our findings showed 
that the risk of MI in cases with high levels of AST 
and LDL was about 24 and 7 times more than the 
control group respectively. 
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Our findings showed that CK-MB levels were 
significantly higher in cases with MI, and many 
other studies reported the good performance of this 
biomarker in detection of MI (19,20). In contrast, it 
is also reported that the weak sensitivity and 
specificity for CK-MB in this regard and its 
accuracy is still controversial, especially after 
resuscitation (21). However, it seems that it can be 
a useful marker along with other diagnostic 
approaches for MI detection. 
Regarding FBS, our results were in the same 
line with the study of Abbasi et al., which 
considered the high levels of FBS as one of the MI 
risk factors (22). It is remarkable that the study of 
Ishihara et al. showed that hyperglycemia is 
associated with MI and that it can deteriorate the 
prognosis in both diabetic and non-diabetic 
individuals (23). It is also reported that 
hyperglycemia is associated with the development 
of kidney injury and left ventricular dysfunction 
(because of the no-reflow phenomenon) in patients 
with MI (24, 25). Hyperglycemia can affect MI 
through several ways such as induction of 
electrophysiological alterations following 
arrhythmias, ischemic preconditioning, coagulation 
alteration, which likely to increase thrombosis 
activation, inflammatory amplification, and 
inducing endothelial dysfunction (26). 
Among liver enzymes, levels of AST and ALT 
were elevated in MI patients significantly in 
comparison to the control group, which was also 
reported in the study of Lofthus et al. (27). About 
ALP, although we did not find any relationships 
with MI, Nunes et al. found that high levels of ALP 
can act as a diagnostic factor for decreased survival 
rate and renal function in male diabetic patients 
with MI (28). 
Besides, our check results showed that the 
probability of MI in individuals with high levels of 
AST is nearly 17 times more than the control group. 
This enzyme was one of the first cardiac biomarkers 
used in the year 1954, and because of weak 
specificity for the matter, it is no longer used as a 
gold standard. Thereafter, total creatine kinase level 
and lactate dehydrogenase were used as a 
diagnostic factor for MI by the years 1959 and 1960 
respectively (29,30). Eventually, the World Health 
Organization (WHO) suggested using these three 
factors for MI diagnosis by the year 1979, which 
was altered by the immunoassay’s development in 
1980 (31,32). 
Regarding lipids profile, our findings showed 
that cases with high levels of LDL are at risk of MI 
7 times more than the control group, which is in the 
same line with previous studies (33,34). However 
other members of lipids, although we could not find 
any relationships, previous studies indicated a 
relationship between low levels of HDL (35) and 
high levels of triglycerides (36) and risk of MI. 
However, facts regarding HDL are still 
controversial (37). 
Our investigation indicated that high levels of 
ESR could be related to poor prognosis of MI, 
which was previously reported in several studies 
similarly (38,39). Therefore, it seems that ESR can 
be considered as a prognostic factor for monitoring 
of patients with MI to prevent the heart acute 
attacks (40). 
As a strength of the study, to our knowledge, 
there is no investigation regarding the association 
of blood biomarkers with MI in this extent, at least 
in Iran. However, due to the retrospective nature of 
the study as a limitation, it is recommended that a 
comprehensive longitudinal cohort study be 
designed in order to examine the accurate role of 
these markers in MI. 
In conclusion, we found that levels of CK-MB, 
FBS, AST, ALT, and ESR were significantly higher 
in patients with MI compared to the control group. 
Besides, our results indicated that individuals with 
high levels of AST were at risk of MI about 24 
times more than the control group. Moreover, this 
risk was also 7 times higher in cases with high 
levels of LDL. Hence, clinicians may consider these 
factors as a valuable diagnostic or prognostic factor 
for patients with MI to prevent the next attacks and 
for a healthy population to prevent the first attack. 
Nevertheless, more comprehensive studies in 
different regions need to be done to avoid the 
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